TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7800329

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (1 mg), administered at admission and repeated 6 hours later if labor was not established
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative management for 24 hours
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (1 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 100
Study: 2181769

Group type: EXPERIMENTAL
Intervention: Furosemide administered post-TURP
Number of subjects: 14

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 14
Study: 383033

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide with methyldopa
Number of subjects: 16

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 16
Study: 30587533

Group type: EXPERIMENTAL
Intervention: Mupirocin (5 days of intranasal plus topical application to the intranasal, periumbilical, and perianal areas)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control (no mupirocin)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Mupirocin (5 days of intranasal plus topical application)
Number of subjects: 155
Study: 28939642

Group type: EXPERIMENTAL
Intervention: High-fat Western diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-fat traditional Hispanic diet
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dietary fat quality in BPRHS subset
Number of subjects: 42
Study: 26595029

Group type: COMPARATOR
Intervention: Classic vertical plication (group A)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vertical plication with customized horizontal plications (group B)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 98
Study: 23571650

Group type: EXPERIMENTAL
Intervention: Impact® (IMN)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isosource® (STD)
Number of subjects: 8
Study: 21771255

Group type: EXPERIMENTAL
Intervention: Conventional TENS (high frequency, low intensity)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Acupuncture-like TENS (AL-TENS, low frequency, high intensity)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo TENS (no current)
Number of subjects: 121
Study: 19454869

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg daily
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Duloxetine (overall phase)
Number of subjects: 350
Study: 16777518

Group type: EXPERIMENTAL
Intervention: High-resolution ECGs
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard ECGs
Number of subjects: 13
Study: 12532318

Group type: EXPERIMENTAL
Intervention: Temazepam (7.5-30 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Temazepam plus CBT
Number of subjects: 60
Study: 10364861

Group type: EXPERIMENTAL
Intervention: Nellcor N-3000 pulse oximeter
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nellcor N-200 pulse oximeter
Number of subjects: 22
Study: 8652325

Group type: EXPERIMENTAL
Intervention: Rocuronium 6 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vecuronium 1 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 2049961

Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg orally once daily for 3 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Co-trimoxazole (320/1,600 mg orally once daily for 3 weeks)
Number of subjects: 52
Study: 6388218

Group type: EXPERIMENTAL
Intervention: Danazol (100 mg, 2 capsules a day for the first month, then 1 capsule a day up to 6 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (2 capsules a day for the first month, then 1 capsule a day up to 6 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30991984

Group type: EXPERIMENTAL
Intervention: Piezocision-assisted flapless corticotomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional orthodontic treatment
Number of subjects: 34
Study: 29923427

Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study: 26851146

Group type: EXPERIMENTAL
Intervention: Low serum osmolality (≤284 mOsm/kg)
Number of subjects: 3744

Group type: EXPERIMENTAL
Intervention: 15 mOsm/kg decrease in osmolality
Number of subjects: 3744

Group type: COMPARATOR
Intervention: Normal serum osmolality (285 to 300 mOsm/kg)
Number of subjects: 3744

Group type: COMPARATOR
Intervention: High serum osmolality (≥300 mOsm/kg)
Number of subjects: 3744
Study: 25434622

Group type: EXPERIMENTAL
Intervention: EMLA® cream (eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) applied for 60 minutes prior to cryotherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo cream applied for 60 minutes prior to cryotherapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: EMLA® cream (for those with more than 1 wart)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: EMLA® cream (for those with only 1 wart)
Number of subjects: 64
Study: 23167380

Group type: EXPERIMENTAL
Intervention: Rational-Emotive Behavior Therapy (REBT) for 45 days (ten sessions)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study: 21126954

Group type: EXPERIMENTAL
Intervention: FPV/r100
Number of subjects: 0

Group type: COMPARATOR
Intervention: FPV/r200
Number of subjects: 0
Study: 17141936

Group type: EXPERIMENTAL
Intervention: Compression force during CPR
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Compression depth during CPR
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Force needed to reach 38 mm compression depth (F38)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Mean compression force
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Chest stiffness
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Residual force during decompression
Number of subjects: 91
Study: 15851952

Group type: EXPERIMENTAL
Intervention: Single lyophilisate application of sodium fluorescein (204 microg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Three conventional eye drops of sodium fluorescein (40 microl each, 68 microg total)
Number of subjects: 22
Study: 11988381

Group type: EXPERIMENTAL
Intervention: Tailored print plus tailored telephone counseling (TP+TC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored print (TP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 9934749

Group type: EXPERIMENTAL
Intervention: 6 million units (MU) of lymphoblastoid interferon alpha (IFN) daily for the first 2 weeks, then thrice weekly for an additional 14 or 22 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 9 million units (MU) of lymphoblastoid interferon alpha (IFN) daily for the first 2 weeks, then thrice weekly for an additional 14 or 22 weeks
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 9 million units (MU) of lymphoblastoid interferon alpha (IFN)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 6 million units (MU) of lymphoblastoid interferon alpha (IFN)
Number of subjects: 84
Study: 7594330

Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg (n = 9)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: lansoprazole (LPZ) 30 mg (n = 16)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus plaunotol 480 mg (n = 13)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus ecabet sodium 2 g (n = 11)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus clarithromycin 600 mg (the first 2 weeks; n = 11)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus plaunotol 480 mg plus clarithromycin 600 mg (the first 2 weeks; n = 13)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: LPZ 30 mg plus ecabet sodium 2 g plus amoxicillin 1,500 mg (the first 2 weeks; n = 13)
Number of subjects: 86
Study: 2924606

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 83808

Group type: EXPERIMENTAL
Intervention: Kystosol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Glycine
Number of subjects: 27
Study: 31330023

Group type: EXPERIMENTAL
Intervention: Stress Proffen app-based intervention
Number of subjects: 25
Study: 31570733

Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate (AM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 28503982

Group type: EXPERIMENTAL
Intervention: Cervical disc replacement
Number of subjects: 151

Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Non-neurogenic pain drawings (Ransford method)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Markings in the head region
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Markings in the neck and lower arm region
Number of subjects: 151
Study: 26627989

Group type: EXPERIMENTAL
Intervention: LAA closure
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Long-term warfarin therapy
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Overall comparison of major bleeding rates
Number of subjects: 1114
Study: 23645099

Group type: EXPERIMENTAL
Intervention: Calcitriol administration (0.25 μg bid for 1 week)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (300,000 IU single oral dose)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 38
Study: 20236252

Group type: EXPERIMENTAL
Intervention: 360° laser trabeculoplasty and topical betaxolol eye drops B.I.D.
Number of subjects: 128
Study: 19026450

Group type: EXPERIMENTAL
Intervention: Modified Mother-Infant Transaction Program (7 sessions prior to discharge and 2 sessions over 3 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 17257991

Group type: EXPERIMENTAL
Intervention: Retransfusion of washed shed blood or discarding of unwashed blood
Number of subjects: 37

Group type: COMPARATOR
Intervention: Retransfusion of unwashed shed blood
Number of subjects: 37
Study: 15514407

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 138

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Imipramine with lithium addition
Number of subjects: 138

Group type: COMPARATOR
Intervention: Fluvoxamine with lithium addition
Number of subjects: 138
Study: 11527892

Group type: EXPERIMENTAL
Intervention: Albumin administration on the day of oocyte retrieval
Number of subjects: 87

Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (placebo control)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 87
Study: 9085712

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol in light alcohol consumers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg alcohol in light alcohol consumers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg alcohol in moderate alcohol consumers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol in moderate alcohol consumers
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg and 1.0 g/kg alcohol in light consumers (frequency and duration measures)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg alcohol in moderate consumers (duration measure)
Number of subjects: 10
Study: 7942724

Group type: EXPERIMENTAL
Intervention: 1 week of quadruple therapy
Number of subjects: 111

Group type: COMPARATOR
Intervention: 2 weeks of quadruple therapy
Number of subjects: 111
Study: 2598985

Group type: EXPERIMENTAL
Intervention: CI-924 (CI) 600 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CI-924 (CI)
Number of subjects: 35
Study: 788733

Group type: EXPERIMENTAL
Intervention: Synthetic isoquinoline compound (U.K. 2371)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 30903442

Group type: EXPERIMENTAL
Intervention: Self-Affirmation
Number of subjects: 603

Group type: COMPARATOR
Intervention: No Self-Affirmation Control
Number of subjects: 603
Study: 27225535

Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 200
Study: 26653189

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 597

Group type: COMPARATOR
Intervention: Usual chronic obstructive pulmonary disease (control group)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Exercise-related desaturation
Number of subjects: 597
Study: 23131613

Group type: EXPERIMENTAL
Intervention: Hormonal contraceptives (HC women)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Cold Pressor Stress (CPS)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 78
Study: 21618499

Group type: EXPERIMENTAL
Intervention: Preoperative duplex imaging (group 1)
Number of subjects: 293

Group type: COMPARATOR
Intervention: No preoperative duplex imaging (group 2)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) measured with the Short Form 36 questionnaire
Number of subjects: 293
Study: 19099308

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) program and exercises
Number of subjects: 41

Group type: COMPARATOR
Intervention: Exercises (Control group)
Number of subjects: 41
Study: 22765645

Group type: EXPERIMENTAL
Intervention: High-dose levofloxacin 750 mg intravenously once daily, followed by the same dose orally at discharge when clinically improved.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ceftriaxone 2.0 g intravenously once daily plus oral azithromycin 500 mg for 3 consecutive days, followed by oral cefpodoxime 200 mg per day at discharge after clinical improvement.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose levofloxacin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ceftriaxone plus azithromycin
Number of subjects: 40
Study: 15796351

Group type: EXPERIMENTAL
Intervention: Sequestrectomy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Microdiscectomy
Number of subjects: 84
Study: 12036814

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 33
Study: 9857493

Group type: EXPERIMENTAL
Intervention: Implicit measure of strategy discovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit measure of strategy discovery
Number of subjects: 0
Study: 7740334

Group type: EXPERIMENTAL
Intervention: Combined doxorubicin (50 mg/m2 day 1) and vinorelbine (25 mg/m2 days 1 and 8) every 21 days
Number of subjects: 62
Study: 2258080

Group type: EXPERIMENTAL
Intervention: Carboplatin (400 mg/m2 IV every 28 days)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 41
Study: 369643

Group type: EXPERIMENTAL
Intervention: Intermittent compression dressings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard method of care
Number of subjects: 0
Study: 11326179

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 3 mg (group 1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (group 4)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 68
Study: 30678863

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid Receptor Antagonists (MRA)
Number of subjects: 0
Study: 29995743

Group type: EXPERIMENTAL
Intervention: Vaginal antisepsis policies
Number of subjects: 2013

Group type: COMPARATOR
Intervention: No vaginal antisepsis policies
Number of subjects: 2013
Study: 27043452

Group type: EXPERIMENTAL
Intervention: MP‐AzeFlu (Dymista(®), 1 spray/nostril bid)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP, 1 spray/nostril bid)
Number of subjects: 353
Study: 24281730

Group type: EXPERIMENTAL
Intervention: Levocetirizine + Montelukast
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desloratadine + Montelukast
Number of subjects: 40

Group type: COMPARATOR
Intervention: Montelukast (monotherapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antihistamine (monotherapy)
Number of subjects: 40
Study: 23200287

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment for adolescents (MBT-A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 80
Study: 20070811

Group type: EXPERIMENTAL
Intervention: Research papers published in the journal
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative data
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Systematic reviews, randomized control trials, and quasi-experimental design studies
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: All papers
Number of subjects: 168
Study: 18097903

Group type: EXPERIMENTAL
Intervention: Obstetric fistulae treatment
Number of subjects: 160
Study: 15800937

Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 200 mg daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12450694

Group type: EXPERIMENTAL
Intervention: Urease (60 mg) + LT (5 microg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Urease (60 mg) + LT (25 microg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Urease (60 mg)
Number of subjects: 18
Study: 9558681

Group type: EXPERIMENTAL
Intervention: Vibration piezoelectric‐controlled VVIR Sensolog III Siemens pacemaker
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Accelerometer‐controlled VVIR Dash Intermedics pacemaker
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 7617424

Group type: EXPERIMENTAL
Intervention: Pinhole viewing of real ridges
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (non-pinhole viewing) for real ridges
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pinhole viewing of stereograms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions for stereograms
Number of subjects: 0
Study: 2144154

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study: 366085

Group type: EXPERIMENTAL
Intervention: Bromocriptine (30 mg per day in divided doses)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 11
Study: 31894995

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 242
Study: 30909157

Group type: EXPERIMENTAL
Intervention: myPlaybook (web-based alcohol intervention)
Number of subjects: 2449

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 2449
Study: 27880079

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (3 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral erythromycin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Baseline gastric emptying
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Faster gastric emptying
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying
Number of subjects: 30
Study: 22234829

Group type: EXPERIMENTAL
Intervention: ORT and domperidone
Number of subjects: 56

Group type: COMPARATOR
Intervention: ORT alone
Number of subjects: 56
Study: 23615650

Group type: EXPERIMENTAL
Intervention: Watermelon supplementation (L‐citrulline/L‐arginine 6 g/d)
Number of subjects: 12
Study: 21492159

Group type: EXPERIMENTAL
Intervention: Low-probability/high-payout lottery
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: High-probability/low-payout lottery
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Unconditional fixed payment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Conditional fixed payment
Number of subjects: 3

Group type: COMPARATOR
Intervention: Moderate-probability/moderate-payout lottery
Number of subjects: 3
Study: 20077977

Group type: EXPERIMENTAL
Intervention: Tai Chi (intervention not specified in dosage or duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 0
Study: 17130197

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once-daily
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study: 12601628

Group type: EXPERIMENTAL
Intervention: Troglitazone treatment in Group A
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo treatment in Group B
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Troglitazone treatment in Groups B and C
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Troglitazone treatment in all groups
Number of subjects: 87
Study: 10553828

Group type: EXPERIMENTAL
Intervention: 30 mg (2 mL 1.5%)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 45 mg (3 mL 1.5%)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 60 mg (4 mL 1.5%)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Overall incidence of TNS
Number of subjects: 75
Study: 8921789

Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study: 1759534

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 13
Study: 7074797

Group type: EXPERIMENTAL
Intervention: Exercise group (B1)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Exercise and teaching-counseling group (B2)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Routine medical care (Control group A)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 258
Study: 30457668

Group type: EXPERIMENTAL
Intervention: Citicoline (titrated to 2,000 mg/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 29132478

Group type: EXPERIMENTAL
Intervention: Vaginal clindamycin (multiple doses)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral secnidazole (single 2-gm dose)
Number of subjects: 100
Study: 26419215

Group type: EXPERIMENTAL
Intervention: Positioning in neutral
Number of subjects: 218

Group type: COMPARATOR
Intervention: Conventional positioning
Number of subjects: 218
Study: 24511726

Group type: EXPERIMENTAL
Intervention: Multidisciplinary education program in self-care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal care program (Control)
Number of subjects: 60